List view / Grid view
20 March 2019 | By Jeff Martin (Head of Compound Management - Alkermes Inc.)
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.
19 March 2019 | By Aparajita Dubey - Associate Consultant at Prescient Healthcare Group
Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in-vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies, bi-specific…
18 March 2019 | By Drug Target Review
In this In-Depth Focus: realising the promise of laboratory automation in biomedical research, drug discovery from the age of information to the age of intelligence, and transforming drug discovery, development and delivery with flow chemistry.
15 March 2019 | By Drug Target Review
In this In-Depth Focus: AI-driven automated chemistry as a tool to accelerate drug discovery, and a look at network-driven drug discovery
14 March 2019 | By Drug Target Review
In this In-Depth Focus: the importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays, and why do we have no effective treatments for osteoarthritis?
14 March 2019 | By Drug Target Review
In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.
7 February 2019 | By Anthony Pinkerton
Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving…
15 January 2019 | By Douglas J. Swirsky
Immunotherapy and targeted treatments, including targeted chemotherapy, continue to show great potential in cancer care. Future steps in their development will involve improving their ability to treat a wider range of cancers and a broader cross-section of the patient population, especially those for whom current treatments have shown limited efficacy...
11 December 2018 | By Matthias Nees and Malin Åkerfelt (University of Turku - Finland)
Drug discovery is still hampered by the routine use of cell-based models that often fail to recapitulate the truly relevant biological complexity of the corresponding disease. Just moving from two- (2D) towards three-dimensional (3D) cell culture model systems like spheroids and organoids is not enough to generate truly representative and…
10 December 2018 | By Christopher J. Langmead
G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.
10 December 2018 | By Anowarul Amin
In the wake of the human genome project, molecular biology and genetic technologies are tremendously integrating into biomedical research. Currently, PCR, qPCR, and sequencing are key tools in the clinical laboratory for the detection and characterisation of microorganisms and genetic disorders.
10 December 2018 | By NanoTemper Technologies
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
7 December 2018 | By Pushpanathan Muthuirulan
The catastrophic consequences of ever-increasing rates of death from infectious diseases demands new experimental strategies for drug target selection and drug design. Over the last decade, the pharmaceutical industry has been wounded by several issues including failure of drug-development programmes, burgeoning cost of drug development, increasing regulatory control, lack of…
7 December 2018 | By PerkinElmer
Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.
7 December 2018 | By Bio-Techne
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
Follow: